...
首页> 外文期刊>Indian Journal of Radiology and Imaging >Role of ADC values in assessing clinical response and identifying residual disease post-chemo radiation in uterine cervix cancer
【24h】

Role of ADC values in assessing clinical response and identifying residual disease post-chemo radiation in uterine cervix cancer

机译:ADC值在评估子宫子宫颈癌中临床响应和鉴定中的临床响应和鉴定残留疾病中的作用

获取原文
           

摘要

Objectives: To evaluate the role of apparent diffusion coefficient (ADC) values in assessing response after chemo-radiotherapy in cervix cancer and investigate the utility of ADC as a tool to identify residual disease, after the treatment completion. Methods: A prospective study was done in 100 patients with histopathologically proven cancer of uterine cervix who were classified as either complete response (CR) or residual disease posttreatment. MRI was done pretreatment and after 6 weeks post-treatment with chemo-radiation. 53 patients among the cohort also underwent a fluoro-deoxy glucose positron-emission computed tomography (FDG-PET CT). ADC values, change in ADC values, and metabolic activity obtained from FDG-PET CT were correlated with clinical outcome, and statistical analysis was done to determine the better tool for assessing response evaluation between ADC and PET-CT. Results: Residual lesions have notably lower ADC value than that of posttreatment changes. The mean ADC values of residual tumors: 1.26 ± 0.238 × 10sup?3/sup mmsup2/sup/s and mean ADC values of lesions due to posttreatment changes: 1.540 ± 0.218 × 10sup?3/sup mmsup2/sup/s (statistically significant difference between malignant and posttreatment lesions, P 0.05). ADC has 67% sensitivity, 83% specificity, 35% positive predictive values (PPV), 95% negative predictive values (NPV), and 81% accuracy in differentiating residual disease from post treatment changes. PPV, NPV, sensitivity, and specificity with PET-CT were 93%, 89%, 98%, and 73%, respectively. PPV, NPV, sensitivity, and specificity of contrast MRI were 16%, 91%, 58%, and 59%, respectively. Conclusion: Diffusion imaging differentiates residual cervix malignancies from post treatment changes based on ADC values and can be a promising and evocative biomarker. Complimentary use of ADC and PET/CT may increase diagnostic confidence.
机译:目的:评估表观扩散系数(ADC)值在宫颈癌中化疗后评估反应中的作用,并在治疗完成后调查ADC作为鉴定残留疾病的工具的工具。方法:预期研究是在100名患有子宫子宫颈癌症癌症的患者中进行的,被归类为完全反应(Cr)或残留疾病后患者。 MRI进行预处理,并在用化疗后6周后治疗后6周。队列中的53例患者也经过氟 - 脱氧葡萄糖正电子 - 发射计算断层扫描(FDG-PET CT)。 ADC值,ADC值的变化以及从FDG-PET CT获得的代谢活性与临床结果相关,并进行统计分析以确定评估ADC和PET-CT之间的响应评估的更好工具。结果:残留病变明显低于接生变化的ADC值。残留肿瘤的平均ADC值:1.26±0.238×10 3 mm 2 / s,并且由于后处理而平均病变的ADC值变化:1.540±0.218×10 < sup>?3 mm 2 / s(恶性和后处理病变之间的统计学意义差异,p <0.05)。 ADC具有67%的灵敏度,83%的特异性,35%的阳性预测值(PPV),95%的阴性预测值(NPV)和81%的准确性,在治疗后的残留疾病中分化残留疾病。 PPV,NPV,敏感性和PET-CT的特异性分别为93%,89%,98%和73%。对比度MRI的PPV,NPV,敏感度和特异性分别为16%,91%,58%和59%。结论:扩散成像与基于ADC值的后治疗变化的残留宫颈恶性肿瘤区别分析,并且可以是有前途和令人兴奋的生物标志物。免费使用ADC和PET / CT可能会增加诊断信心。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号